Get notified when VKTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Auditor Change (new) — The company changed its independent auditor from Marcum LLP to CBIZ CPAs P.C. for the fiscal year ended December 31, 2025, which may warrant further investigation.
Viking Therapeutics files preliminary prospectus for common stock and concurrent convertible note offerings, terms not yet set
Filed September 23, 2026 · ~2 min read
Key Changes
-
high
Offering size and price are left blank in this preliminary 424B5; last reported sale price was $40.85 on Sept 22, 2026.
The Offering verify on EDGAR → -
high
Concurrent offering of convertible senior notes due 2032, with principal amount and interest rate also blank; not contingent on equity offering.
The Offering verify on EDGAR → -
medium
Net proceeds intended for clinical development of VK2735 and VK3019 programs and general corporate purposes.
Use of Proceeds verify on EDGAR →
4 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade VKTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 26, 2026 · How we verify